Brief: Zynerba Pharmaceuticals Announces Issuance Of New U.S. Patent For Zygel For Treatment Of 22q11.2 Deletion Syndrome
02/11/2022 11:35
Nov 2 (Reuters) - Zynerba Pharmaceuticals Inc ZYNE.O :
* ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW U.S.
PATENT
FOR ZYGEL™ FOR THE TREATMENT OF 22Q11.2 DELETION SYNDROME
Source text for Eikon: ID:nGNX6tvBJ8
Further company coverage: ZYNE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Zynerba Pharmaceuticals
See all newsBrief: Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals
Brief: Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary